Cancer Research

Cancer Research

by Pininvest Analysis

Challenging times for Celgene

Pininvest Analysis on Health Care

Revlimid, a drug for multiple myeloma, is the main stay of Celgene’s business (approx. 2/3 of 2017 $13bn turnover) – the drug also highlights the challenges of large biopharmaceutical companies priced for growth

Pininvest Analysis

Pininvest Analysis

Experienced professionals, seeking to combine financial acumen and business expertise